A PERFORMANCE NOT TO BE MISSED...

Dear Healthcare Professional | November 2020

Adcock Ingram is pleased to announce a **reduction of 15% in the price of Remsima 100 mg Infliximab.**

REMSIMA® is approved for the same indications as reference infliximab: RA, AS, PsA, psoriasis, Crohn's disease and ulcerative colitis [1]

Product	Reg. number	Schedule	Bar Code	Nappi code	Price (excl. VAT)	Price (incl. VAT)
Remsima® 100 mg	52/30.1/0309	S4	6004406006493	3001518001	**R 3132.06**	**R 3601.87**

Our team is dedicated to providing you and your practice with not only a professional service, but access to the latest clinical and therapeutic information. You are most welcome to contact Adcock Ingram to facilitate an enquiry. We look forward to being of service to you, your practice and your patients.

15% PRICE REDUCTION

Yours sincerely,

Chanel Chengan
Marketing and Sales Manager: Biologics
Customer Care Line 0860 ADCOCK I 232625
Email: Info.Biosimilars@adcock.com

Remsima® Infliximab
A biological within reach

References: 1. Blair HA, Deeks ED. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. *BioDrugs* 2016;**30**:469–480.

HEALTHCARE CELLTRION

S4 REMSIMA® powder for concentrate for solution for infusion. Each vial contains: 100 mg infliximab. Reg. No. 52/30.1/0309. For full prescribing information refer to the package insert approved by the medicines regulatory authority. Adcock Ingram Limited. Reg. No. 1949/034385/06. Private Bag X69, Bryanston, 2021. Tel. + 27 11 635 0000. www.adcock.com 202011191071994

adcock ingram